The Annals of pharmacotherapy
-
To evaluate the use of recombinant factor VIIa (rFVIIa) to reverse major bleeding from newer parenteral anticoagulant therapy. ⋯ rFVIIa may be considered to manage major refractory bleeding from newer parenteral anticoagulant agents when the benefit is thought to outweigh the thrombotic risk.
-
The benefits of inhaled corticosteroids (ICS) in reducing the mortality related to chronic obstructive pulmonary disease (COPD) are controversial. ⋯ ICS were found to be associated with a reduction in mortality rate when compared to LABA among patients with COPD. However, the ICS/LABA combination therapy did not provide any additional benefit on mortality when compared to ICS monotherapy.
-
Gastrointestinal (GI) adverse effects are common with oral opioid treatment. ⋯ The economic burden of GI events coincident with opioid treatment is significant for patients with a GI event recorded in claims. Reducing GI adverse effects has potential cost savings for the health-care system.
-
To review the current state of the science regarding intravenous fat emulsions (IVFEs), with an emphasis on their safety profile. ⋯ The results of this review demonstrate that IVFEs are well tolerated when administered in accordance with guideline recommendations.